Titre : Protein-tyrosine kinases

Protein-tyrosine kinases : Questions médicales fréquentes

Termes MeSH sélectionnés :

Interferon beta-1a

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment diagnostiquer une dysrégulation des kinases à tyrosine ?

Des tests sanguins et des biopsies peuvent révéler des anomalies dans l'activité des kinases.
Kinases Biopsie Tests sanguins
#2

Quels marqueurs sont utilisés pour le diagnostic ?

Les marqueurs tumoraux comme le CA 19-9 peuvent indiquer une activité kinase anormale.
Marqueurs tumoraux Kinases CA 19-9
#3

Les tests génétiques sont-ils utiles ?

Oui, ils peuvent identifier des mutations dans les gènes codant pour les kinases à tyrosine.
Tests génétiques Mutations Kinases
#4

Quels examens d'imagerie sont recommandés ?

L'IRM et le scanner peuvent aider à visualiser les tumeurs associées aux kinases.
IRM Scanner Tumeurs
#5

Les antécédents familiaux influencent-ils le diagnostic ?

Oui, des antécédents de cancers peuvent augmenter le risque de dysrégulation des kinases.
Antécédents familiaux Cancer Kinases

Symptômes 5

#1

Quels symptômes sont liés à une suractivité des kinases ?

Fatigue, perte de poids, et douleurs osseuses peuvent indiquer une suractivité des kinases.
Fatigue Perte de poids Kinases
#2

Les symptômes varient-ils selon le type de kinase ?

Oui, les symptômes dépendent du type de kinase et de la voie de signalisation affectée.
Kinases Voies de signalisation Symptômes
#3

Y a-t-il des symptômes spécifiques aux cancers ?

Oui, des symptômes comme des masses palpables ou des saignements peuvent survenir.
Cancers Masse palpable Saignements
#4

Les symptômes peuvent-ils être confondus avec d'autres maladies ?

Oui, des symptômes comme la fatigue peuvent être communs à plusieurs maladies.
Fatigue Maladies Symptômes
#5

Comment les symptômes évoluent-ils dans le temps ?

Ils peuvent s'aggraver progressivement, nécessitant une surveillance régulière.
Évolution des symptômes Surveillance Kinases

Prévention 5

#1

Peut-on prévenir les dysfonctionnements des kinases ?

Une alimentation saine et l'exercice régulier peuvent réduire le risque de cancers.
Prévention Alimentation saine Exercice
#2

Les dépistages réguliers sont-ils recommandés ?

Oui, des dépistages peuvent aider à détecter précocement des anomalies liées aux kinases.
Dépistage Anomalies Kinases
#3

Y a-t-il des vaccins préventifs ?

Actuellement, il n'existe pas de vaccins spécifiques pour prévenir les dysfonctionnements des kinases.
Vaccins Prévention Kinases
#4

Le tabagisme influence-t-il le risque ?

Oui, le tabagisme est un facteur de risque connu pour plusieurs cancers liés aux kinases.
Tabagisme Facteurs de risque Kinases
#5

Les facteurs environnementaux jouent-ils un rôle ?

Oui, l'exposition à des substances chimiques peut augmenter le risque de dysfonctionnement des kinases.
Facteurs environnementaux Substances chimiques Kinases

Traitements 5

#1

Quels traitements ciblent les kinases à tyrosine ?

Les inhibiteurs de kinases, comme l'imatinib, sont utilisés pour traiter certains cancers.
Inhibiteurs de kinases Imatinib Traitements
#2

Les traitements sont-ils personnalisés ?

Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques des kinases.
Traitements personnalisés Mutations Kinases
#3

Quels effets secondaires des traitements sont courants ?

Fatigue, nausées et éruptions cutanées sont des effets secondaires fréquents.
Effets secondaires Fatigue Nausées
#4

La radiothérapie est-elle utilisée ?

Oui, la radiothérapie peut être utilisée en complément des traitements ciblés.
Radiothérapie Traitements ciblés Kinases
#5

Les traitements sont-ils efficaces à long terme ?

L'efficacité varie, mais certains patients peuvent bénéficier d'une rémission prolongée.
Efficacité des traitements Rémission Kinases

Complications 5

#1

Quelles complications peuvent survenir avec les kinases ?

Des complications comme la résistance aux traitements et la progression de la maladie peuvent survenir.
Complications Résistance aux traitements Progression de la maladie
#2

Les complications sont-elles réversibles ?

Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes.
Complications Gestion Kinases
#3

Comment les complications affectent-elles le pronostic ?

Les complications peuvent aggraver le pronostic et réduire les chances de rémission.
Pronostic Complications Rémission
#4

Les complications varient-elles selon le type de cancer ?

Oui, les complications peuvent différer selon le type de cancer et la kinase impliquée.
Type de cancer Complications Kinases
#5

Les complications nécessitent-elles des traitements supplémentaires ?

Oui, des traitements supplémentaires peuvent être nécessaires pour gérer les complications.
Traitements supplémentaires Complications Kinases

Facteurs de risque 5

#1

Quels sont les principaux facteurs de risque ?

Les antécédents familiaux, le tabagisme et l'exposition à des produits chimiques sont des facteurs de risque.
Facteurs de risque Antécédents familiaux Tabagisme
#2

L'âge influence-t-il le risque de dysfonctionnement des kinases ?

Oui, le risque augmente généralement avec l'âge, surtout pour certains cancers.
Âge Risque Kinases
#3

Le mode de vie joue-t-il un rôle ?

Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque.
Mode de vie Risque Kinases
#4

Les infections peuvent-elles être un facteur de risque ?

Certaines infections virales, comme le virus d'Epstein-Barr, peuvent augmenter le risque.
Infections Virus d'Epstein-Barr Risque
#5

Y a-t-il des facteurs génétiques impliqués ?

Oui, des mutations génétiques héréditaires peuvent prédisposer à des dysfonctionnements des kinases.
Facteurs génétiques Mutations Kinases
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Protein-tyrosine kinases : Questions médicales les plus fréquentes", "headline": "Protein-tyrosine kinases : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Protein-tyrosine kinases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-05", "dateModified": "2025-04-30", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Protein-tyrosine kinases" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines et peptides de signalisation intracellulaire", "url": "https://questionsmedicales.fr/mesh/D047908", "about": { "@type": "MedicalCondition", "name": "Protéines et peptides de signalisation intracellulaire", "code": { "@type": "MedicalCode", "code": "D047908", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Agammaglobulinaemia tyrosine kinase", "alternateName": "Agammaglobulinaemia Tyrosine Kinase", "url": "https://questionsmedicales.fr/mesh/D000077329", "about": { "@type": "MedicalCondition", "name": "Agammaglobulinaemia tyrosine kinase", "code": { "@type": "MedicalCode", "code": "D000077329", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.025" } } }, { "@type": "MedicalWebPage", "name": "Focal adhesion protein-tyrosine kinases", "alternateName": "Focal Adhesion Protein-Tyrosine Kinases", "url": "https://questionsmedicales.fr/mesh/D051416", "about": { "@type": "MedicalCondition", "name": "Focal adhesion protein-tyrosine kinases", "code": { "@type": "MedicalCode", "code": "D051416", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.049" } } }, { "@type": "MedicalWebPage", "name": "Janus kinases", "alternateName": "Janus Kinases", "url": "https://questionsmedicales.fr/mesh/D053612", "about": { "@type": "MedicalCondition", "name": "Janus kinases", "code": { "@type": "MedicalCode", "code": "D053612", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.124" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Janus kinase 1", "alternateName": "Janus Kinase 1", "url": "https://questionsmedicales.fr/mesh/D053613", "about": { "@type": "MedicalCondition", "name": "Janus kinase 1", "code": { "@type": "MedicalCode", "code": "D053613", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.124.100" } } }, { "@type": "MedicalWebPage", "name": "Janus kinase 3", "alternateName": "Janus Kinase 3", "url": "https://questionsmedicales.fr/mesh/D053616", "about": { "@type": "MedicalCondition", "name": "Janus kinase 3", "code": { "@type": "MedicalCode", "code": "D053616", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.124.300" } } }, { "@type": "MedicalWebPage", "name": "TYK2 Kinase", "alternateName": "TYK2 Kinase", "url": "https://questionsmedicales.fr/mesh/D053634", "about": { "@type": "MedicalCondition", "name": "TYK2 Kinase", "code": { "@type": "MedicalCode", "code": "D053634", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.124.650" } } } ] }, { "@type": "MedicalWebPage", "name": "Mitogen-Activated Protein Kinase Kinases", "alternateName": "Mitogen-Activated Protein Kinase Kinases", "url": "https://questionsmedicales.fr/mesh/D020929", "about": { "@type": "MedicalCondition", "name": "Mitogen-Activated Protein Kinase Kinases", "code": { "@type": "MedicalCode", "code": "D020929", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.200" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "MAP Kinase Kinase 1", "alternateName": "MAP Kinase Kinase 1", "url": "https://questionsmedicales.fr/mesh/D048369", "about": { "@type": "MedicalCondition", "name": "MAP Kinase Kinase 1", "code": { "@type": "MedicalCode", "code": "D048369", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.200.100" } } }, { "@type": "MedicalWebPage", "name": "MAP Kinase Kinase 2", "alternateName": "MAP Kinase Kinase 2", "url": "https://questionsmedicales.fr/mesh/D048370", "about": { "@type": "MedicalCondition", "name": "MAP Kinase Kinase 2", "code": { "@type": "MedicalCode", "code": "D048370", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.200.200" } } }, { "@type": "MedicalWebPage", "name": "MAP Kinase Kinase 3", "alternateName": "MAP Kinase Kinase 3", "url": "https://questionsmedicales.fr/mesh/D048371", "about": { "@type": "MedicalCondition", "name": "MAP Kinase Kinase 3", "code": { "@type": "MedicalCode", "code": "D048371", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.200.300" } } }, { "@type": "MedicalWebPage", "name": "MAP Kinase Kinase 4", "alternateName": "MAP Kinase Kinase 4", "url": "https://questionsmedicales.fr/mesh/D048670", "about": { "@type": "MedicalCondition", "name": "MAP Kinase Kinase 4", "code": { "@type": "MedicalCode", "code": "D048670", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.200.400" } } }, { "@type": "MedicalWebPage", "name": "MAP Kinase Kinase 5", "alternateName": "MAP Kinase Kinase 5", "url": "https://questionsmedicales.fr/mesh/D048671", "about": { "@type": "MedicalCondition", "name": "MAP Kinase Kinase 5", "code": { "@type": "MedicalCode", "code": "D048671", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.200.500" } } }, { "@type": "MedicalWebPage", "name": "MAP Kinase Kinase 6", "alternateName": "MAP Kinase Kinase 6", "url": "https://questionsmedicales.fr/mesh/D048669", "about": { "@type": "MedicalCondition", "name": "MAP Kinase Kinase 6", "code": { "@type": "MedicalCode", "code": "D048669", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.200.600" } } }, { "@type": "MedicalWebPage", "name": "MAP Kinase Kinase 7", "alternateName": "MAP Kinase Kinase 7", "url": "https://questionsmedicales.fr/mesh/D048688", "about": { "@type": "MedicalCondition", "name": "MAP Kinase Kinase 7", "code": { "@type": "MedicalCode", "code": "D048688", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.200.700" } } } ] }, { "@type": "MedicalWebPage", "name": "Syk kinase", "alternateName": "Syk Kinase", "url": "https://questionsmedicales.fr/mesh/D000072377", "about": { "@type": "MedicalCondition", "name": "Syk kinase", "code": { "@type": "MedicalCode", "code": "D000072377", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.650" } } }, { "@type": "MedicalWebPage", "name": "src-Family kinases", "alternateName": "src-Family Kinases", "url": "https://questionsmedicales.fr/mesh/D019061", "about": { "@type": "MedicalCondition", "name": "src-Family kinases", "code": { "@type": "MedicalCode", "code": "D019061", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.800" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "CSK tyrosine-protein kinase", "alternateName": "CSK Tyrosine-Protein Kinase", "url": "https://questionsmedicales.fr/mesh/D000081247", "about": { "@type": "MedicalCondition", "name": "CSK tyrosine-protein kinase", "code": { "@type": "MedicalCode", "code": "D000081247", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.800.158" } } } ] }, { "@type": "MedicalWebPage", "name": "ZAP-70 Protein-tyrosine kinase", "alternateName": "ZAP-70 Protein-Tyrosine Kinase", "url": "https://questionsmedicales.fr/mesh/D051746", "about": { "@type": "MedicalCondition", "name": "ZAP-70 Protein-tyrosine kinase", "code": { "@type": "MedicalCode", "code": "D051746", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.568.900" } } } ], "about": { "@type": "MedicalCondition", "name": "Protein-tyrosine kinases", "alternateName": "Protein-Tyrosine Kinases", "code": { "@type": "MedicalCode", "code": "D011505", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Angela L Tyner", "url": "https://questionsmedicales.fr/author/Angela%20L%20Tyner", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, Illinois, USA; University of Illinois Cancer Center, University of Illinois at Chicago, Chicago, Illinois, USA. Electronic address: atyner@uic.edu." } }, { "@type": "Person", "name": "Eiji Kinoshita", "url": "https://questionsmedicales.fr/author/Eiji%20Kinoshita", "affiliation": { "@type": "Organization", "name": "Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan." } }, { "@type": "Person", "name": "Emiko Kinoshita-Kikuta", "url": "https://questionsmedicales.fr/author/Emiko%20Kinoshita-Kikuta", "affiliation": { "@type": "Organization", "name": "Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan." } }, { "@type": "Person", "name": "Tohru Koike", "url": "https://questionsmedicales.fr/author/Tohru%20Koike", "affiliation": { "@type": "Organization", "name": "Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan." } }, { "@type": "Person", "name": "Gongqin Sun", "url": "https://questionsmedicales.fr/author/Gongqin%20Sun", "affiliation": { "@type": "Organization", "name": "Department of Cell and Molecular Biology, University of Rhode Island, Kingston, RI, United States." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a.", "datePublished": "2022-07-19", "url": "https://questionsmedicales.fr/article/35878575", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.nicl.2022.103109" } }, { "@type": "ScholarlyArticle", "name": "Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple Sclerosis.", "datePublished": "2023-07-20", "url": "https://questionsmedicales.fr/article/37473734", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1159/000532022" } }, { "@type": "ScholarlyArticle", "name": "Considerations for Use of Pharmacodynamic Biomarkers to Support Biosimilar Development - (III) A Randomized Trial with Interferon Beta-1a Products.", "datePublished": "2022-12-02", "url": "https://questionsmedicales.fr/article/36324229", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/cpt.2784" } }, { "@type": "ScholarlyArticle", "name": "Assessment of adherence to, and persistence with, an electromechanical autoinjector for subcutaneous interferon beta-1a injections for multiple sclerosis treatment over 3 years.", "datePublished": "2023-06-07", "url": "https://questionsmedicales.fr/article/37273189", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/17425247.2023.2221432" } }, { "@type": "ScholarlyArticle", "name": "Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif™) using B cell receptor repertoire analysis.", "datePublished": "2022-07-14", "url": "https://questionsmedicales.fr/article/35853357", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jneuroim.2022.577932" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines et peptides de signalisation intracellulaire", "item": "https://questionsmedicales.fr/mesh/D047908" }, { "@type": "ListItem", "position": 5, "name": "Protein-tyrosine kinases", "item": "https://questionsmedicales.fr/mesh/D011505" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Protein-tyrosine kinases - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Protein-tyrosine kinases", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Protein-tyrosine kinases", "description": "Comment diagnostiquer une dysrégulation des kinases à tyrosine ?\nQuels marqueurs sont utilisés pour le diagnostic ?\nLes tests génétiques sont-ils utiles ?\nQuels examens d'imagerie sont recommandés ?\nLes antécédents familiaux influencent-ils le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Interferon+beta-1a#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Protein-tyrosine kinases", "description": "Quels symptômes sont liés à une suractivité des kinases ?\nLes symptômes varient-ils selon le type de kinase ?\nY a-t-il des symptômes spécifiques aux cancers ?\nLes symptômes peuvent-ils être confondus avec d'autres maladies ?\nComment les symptômes évoluent-ils dans le temps ?", "url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Interferon+beta-1a#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Protein-tyrosine kinases", "description": "Peut-on prévenir les dysfonctionnements des kinases ?\nLes dépistages réguliers sont-ils recommandés ?\nY a-t-il des vaccins préventifs ?\nLe tabagisme influence-t-il le risque ?\nLes facteurs environnementaux jouent-ils un rôle ?", "url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Interferon+beta-1a#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Protein-tyrosine kinases", "description": "Quels traitements ciblent les kinases à tyrosine ?\nLes traitements sont-ils personnalisés ?\nQuels effets secondaires des traitements sont courants ?\nLa radiothérapie est-elle utilisée ?\nLes traitements sont-ils efficaces à long terme ?", "url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Interferon+beta-1a#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Protein-tyrosine kinases", "description": "Quelles complications peuvent survenir avec les kinases ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles le pronostic ?\nLes complications varient-elles selon le type de cancer ?\nLes complications nécessitent-elles des traitements supplémentaires ?", "url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Interferon+beta-1a#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Protein-tyrosine kinases", "description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de dysfonctionnement des kinases ?\nLe mode de vie joue-t-il un rôle ?\nLes infections peuvent-elles être un facteur de risque ?\nY a-t-il des facteurs génétiques impliqués ?", "url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Interferon+beta-1a#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysrégulation des kinases à tyrosine ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des biopsies peuvent révéler des anomalies dans l'activité des kinases." } }, { "@type": "Question", "name": "Quels marqueurs sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les marqueurs tumoraux comme le CA 19-9 peuvent indiquer une activité kinase anormale." } }, { "@type": "Question", "name": "Les tests génétiques sont-ils utiles ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent identifier des mutations dans les gènes codant pour les kinases à tyrosine." } }, { "@type": "Question", "name": "Quels examens d'imagerie sont recommandés ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'IRM et le scanner peuvent aider à visualiser les tumeurs associées aux kinases." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de cancers peuvent augmenter le risque de dysrégulation des kinases." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une suractivité des kinases ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Fatigue, perte de poids, et douleurs osseuses peuvent indiquer une suractivité des kinases." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type de kinase ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes dépendent du type de kinase et de la voie de signalisation affectée." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques aux cancers ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes comme des masses palpables ou des saignements peuvent survenir." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils être confondus avec d'autres maladies ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes comme la fatigue peuvent être communs à plusieurs maladies." } }, { "@type": "Question", "name": "Comment les symptômes évoluent-ils dans le temps ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent s'aggraver progressivement, nécessitant une surveillance régulière." } }, { "@type": "Question", "name": "Peut-on prévenir les dysfonctionnements des kinases ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation saine et l'exercice régulier peuvent réduire le risque de cancers." } }, { "@type": "Question", "name": "Les dépistages réguliers sont-ils recommandés ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des dépistages peuvent aider à détecter précocement des anomalies liées aux kinases." } }, { "@type": "Question", "name": "Y a-t-il des vaccins préventifs ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de vaccins spécifiques pour prévenir les dysfonctionnements des kinases." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il le risque ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme est un facteur de risque connu pour plusieurs cancers liés aux kinases." } }, { "@type": "Question", "name": "Les facteurs environnementaux jouent-ils un rôle ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des substances chimiques peut augmenter le risque de dysfonctionnement des kinases." } }, { "@type": "Question", "name": "Quels traitements ciblent les kinases à tyrosine ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les inhibiteurs de kinases, comme l'imatinib, sont utilisés pour traiter certains cancers." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques des kinases." } }, { "@type": "Question", "name": "Quels effets secondaires des traitements sont courants ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Fatigue, nausées et éruptions cutanées sont des effets secondaires fréquents." } }, { "@type": "Question", "name": "La radiothérapie est-elle utilisée ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la radiothérapie peut être utilisée en complément des traitements ciblés." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces à long terme ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité varie, mais certains patients peuvent bénéficier d'une rémission prolongée." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les kinases ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme la résistance aux traitements et la progression de la maladie peuvent survenir." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes." } }, { "@type": "Question", "name": "Comment les complications affectent-elles le pronostic ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent aggraver le pronostic et réduire les chances de rémission." } }, { "@type": "Question", "name": "Les complications varient-elles selon le type de cancer ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent différer selon le type de cancer et la kinase impliquée." } }, { "@type": "Question", "name": "Les complications nécessitent-elles des traitements supplémentaires ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des traitements supplémentaires peuvent être nécessaires pour gérer les complications." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux, le tabagisme et l'exposition à des produits chimiques sont des facteurs de risque." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque de dysfonctionnement des kinases ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque augmente généralement avec l'âge, surtout pour certains cancers." } }, { "@type": "Question", "name": "Le mode de vie joue-t-il un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque." } }, { "@type": "Question", "name": "Les infections peuvent-elles être un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections virales, comme le virus d'Epstein-Barr, peuvent augmenter le risque." } }, { "@type": "Question", "name": "Y a-t-il des facteurs génétiques impliqués ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des mutations génétiques héréditaires peuvent prédisposer à des dysfonctionnements des kinases." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 30/04/2025

Contenu vérifié selon les dernières recommandations médicales

Sous-catégories

18 au total
└─

Agammaglobulinaemia tyrosine kinase

Agammaglobulinaemia Tyrosine Kinase D000077329 - D12.776.476.568.025
└─

Focal adhesion protein-tyrosine kinases

Focal Adhesion Protein-Tyrosine Kinases D051416 - D12.776.476.568.049
└─

Janus kinases

Janus Kinases D053612 - D12.776.476.568.124
└─

Mitogen-Activated Protein Kinase Kinases

Mitogen-Activated Protein Kinase Kinases D020929 - D12.776.476.568.200
└─

Syk kinase

Syk Kinase D000072377 - D12.776.476.568.650
└─

src-Family kinases

src-Family Kinases D019061 - D12.776.476.568.800
└─

ZAP-70 Protein-tyrosine kinase

ZAP-70 Protein-Tyrosine Kinase D051746 - D12.776.476.568.900
└─└─

Janus kinase 1

Janus Kinase 1 D053613 - D12.776.476.568.124.100
└─└─

Janus kinase 3

Janus Kinase 3 D053616 - D12.776.476.568.124.300
└─└─

TYK2 Kinase

TYK2 Kinase D053634 - D12.776.476.568.124.650
└─└─

MAP Kinase Kinase 1

MAP Kinase Kinase 1 D048369 - D12.776.476.568.200.100
└─└─

MAP Kinase Kinase 2

MAP Kinase Kinase 2 D048370 - D12.776.476.568.200.200
└─└─

MAP Kinase Kinase 3

MAP Kinase Kinase 3 D048371 - D12.776.476.568.200.300
└─└─

MAP Kinase Kinase 4

MAP Kinase Kinase 4 D048670 - D12.776.476.568.200.400
└─└─

MAP Kinase Kinase 5

MAP Kinase Kinase 5 D048671 - D12.776.476.568.200.500
└─└─

MAP Kinase Kinase 6

MAP Kinase Kinase 6 D048669 - D12.776.476.568.200.600
└─└─

MAP Kinase Kinase 7

MAP Kinase Kinase 7 D048688 - D12.776.476.568.200.700
└─└─

CSK tyrosine-protein kinase

CSK Tyrosine-Protein Kinase D000081247 - D12.776.476.568.800.158

Auteurs principaux

Angela L Tyner

3 publications dans cette catégorie

Affiliations :
  • Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, Illinois, USA; University of Illinois Cancer Center, University of Illinois at Chicago, Chicago, Illinois, USA. Electronic address: atyner@uic.edu.
Publications dans "Protein-tyrosine kinases" :

Eiji Kinoshita

3 publications dans cette catégorie

Affiliations :
  • Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.

Emiko Kinoshita-Kikuta

3 publications dans cette catégorie

Affiliations :
  • Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.

Tohru Koike

3 publications dans cette catégorie

Affiliations :
  • Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.

Gongqin Sun

3 publications dans cette catégorie

Affiliations :
  • Department of Cell and Molecular Biology, University of Rhode Island, Kingston, RI, United States.

Wanian M Alwanian

2 publications dans cette catégorie

Affiliations :
  • Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, Illinois, USA.
Publications dans "Protein-tyrosine kinases" :

Swati Jaiswal

2 publications dans cette catégorie

Affiliations :
  • University of Massachusetts Chan Medical School, Worcester, United States. Electronic address: swati.jaiswal@umassmed.edu.

Terry W Moody

2 publications dans cette catégorie

Affiliations :
  • Center for Cancer Training, NCI, and Digestive Diseases Branch, NIDDK, NIH, Bethesda, MD 20892, USA.

Robert T Jensen

2 publications dans cette catégorie

Affiliations :
  • Center for Cancer Training, NCI, and Digestive Diseases Branch, NIDDK, NIH, Bethesda, MD 20892, USA.

Cristina Lao-Peregrin

2 publications dans cette catégorie

Affiliations :
  • Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :

Guoqing Xiang

2 publications dans cette catégorie

Affiliations :
  • Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA; Department of Biochemistry, Weill Cornell Medicine, New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :

Jihye Kim

2 publications dans cette catégorie

Affiliations :
  • Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :

Ipsit Srivastava

2 publications dans cette catégorie

Affiliations :
  • Department of Biochemistry, Weill Cornell Medicine, New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :

Alexandra B Fall

2 publications dans cette catégorie

Affiliations :
  • Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :

Danielle M Gerhard

2 publications dans cette catégorie

Affiliations :
  • Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :

Piia Kohtala

2 publications dans cette catégorie

Affiliations :
  • Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :

Daegeon Kim

2 publications dans cette catégorie

Affiliations :
  • Department of Life Sciences, Yeongnam University, Gyeongsan, Gyeongbuk 38451, South Korea.
Publications dans "Protein-tyrosine kinases" :

Minseok Song

2 publications dans cette catégorie

Affiliations :
  • Department of Life Sciences, Yeongnam University, Gyeongsan, Gyeongbuk 38451, South Korea.
Publications dans "Protein-tyrosine kinases" :

Mikel Garcia-Marcos

2 publications dans cette catégorie

Affiliations :
  • Department of Biochemistry, Boston University School of Medicine, Boston, MA 02118, USA.
Publications dans "Protein-tyrosine kinases" :

Joshua Levitz

2 publications dans cette catégorie

Affiliations :
  • Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA; Department of Biochemistry, Weill Cornell Medicine, New York, NY 10065, USA. Electronic address: jtl2003@med.cornell.edu.
Publications dans "Protein-tyrosine kinases" :

Sources (5804 au total)

Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a.

Myelin water imaging is a magnetic resonance imaging (MRI) technique that quantifies myelin damage and repair in multiple sclerosis (MS) via the myelin water fraction (MWF).... In this substudy of a phase 3 therapeutic trial, OPERA II, MWF was assessed in relapsing MS participants assigned to interferon beta-1a (IFNb-1a) or ocrelizumab (OCR) during a two-year double-blind pe... MWF in normal appearing white matter (NAWM), including both whole brain NAWM and 5 white matter structures, and chronic lesions, was assessed in 29 OCR and 26 IFNb-1a treated participants at weeks 0, ... Linear mixed-effects models of data from baseline to week 96 showed a difference in the change in MWF over time favouring ocrelizumab in all NAWM regions. At week 192, lesion MWF was lower for partici... Ocrelizumab appears to protect against demyelination in MS NAWM and chronic lesions and may allow for a more permissive micro environment for remyelination to occur in focal and diffusely damaged tiss...

Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple Sclerosis.

Multiple sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease that secondarily leads to axonal loss and associated brain atrophy. Disease-modifying drugs (DMDs) have previously be... Sixty Caucasian female patients with relapsing-remitting MS undergo blood sample testing for 15 blood parameters at baseline, 1 month, 3 months, and 6 months after treatment by GA or IFN (started as t... A statistically significant difference in the change after 6 months was found in the parameter monocytes (relative count) in the group of patients treated with IFN. The median increase was 27.8%. Chan... Innate immunity has long been neglected in MS immunopathology. The findings suggest that IFN treatment may modulate the immune response in MS by affecting monocyte function and may provide insight int...

Assessment of adherence to, and persistence with, an electromechanical autoinjector for subcutaneous interferon beta-1a injections for multiple sclerosis treatment over 3 years.

Self-administration of subcutaneous interferon beta-1a (sc IFN β-1a) can be achieved with the RebiSmart® electromechanical autoinjector. This study investigated adherence to, and duration of persisten... This retrospective, observational study utilized data from RebiSmart® devices, recorded on the MSdialog database, between January 2014 and November 2019. Adherence and persistence were evaluated over ... The population of RebiSmart® users (... People living with MS were highly adherent to use of the RebiSmart® device, with higher persistence generally observed for older and/or male individuals....

Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif™) using B cell receptor repertoire analysis.

A significant proportion of multiple sclerosis (MS) patients treated with interferon beta-1a (Rebif™) develop anti-drug antibodies (ADA) with a negative impact on treatment efficacy. We hypothesized t...

The impact of metformin use on the outcomes of relapse-remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open-label randomized controlled trial.

Multiple sclerosis (MS) is a chronic demyelinating neurodegenerative disorder. Elevated levels of pro-inflammatory mediators and some oxidative stress parameters can accelerate the demyelination proce... Eighty RRMS patients were equally divided into 2 groups: the intervention group receiving IFNβ-1a plus 2 gm of metformin once daily and the control group receiving IFNβ-1a alone. Interleukin 17 (IL17)... At baseline, there were no statistically significant differences between the two groups (p > 0.05). After 6 months, the change in the median (interquartile range) of the results for both the intervent... Adding metformin to IFNβ-1a demonstrated a potential effect on an oxidative stress marker (MDA). However, there is no statistically significant effect on immunological, MRI and clinical outcomes. We r... ClinicalTrials.gov number: NCT05298670, 28/3/2022....

Prolonged Interferon-Stimulated Gene and Protein Signatures in Multiple Sclerosis Induced by PEGylated IFN-β-1a Compared to Non-PEGylated IFN-β-1a.

Interferon (IFN)-β-1a (Avonex) and longer half-life, polyethylene glycol-conjugated IFN-β-1a (PEG-IFN-β-1a, Plegridy), may generate different molecular responses. We identified different short-term an...

Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis: The CONNECT Randomized Clinical Trial.

With few approved multiple sclerosis therapies in the pediatric population, there is a need for further approved treatment options. Limited data exist for dimethyl fumarate (DMF) treatment in pediatri... To compare the efficacy, safety, and tolerability of DMF vs intramuscular interferon β-1a (IFNβ-1a) in POMS.... The CONNECT study was an active-controlled, open-label, rater-blinded 96-week randomized clinical trial in patients with POMS aged 10 to less than 18 years treated between August 2014 and November 202... Patients were randomized to DMF or IFNβ-1a.... The primary end point was the proportion of patients free of new or newly enlarging (N or NE) T2 hyperintense lesions at week 96 among trial completers. Secondary end points included number of N or NE... Among 150 patients with POMS in the intention-to-treat (ITT) population (median [range] age, 15 [10-17] years; 101 [67.3%] female patients), 78 individuals received DMF and 72 individuals received IFN... This study found that more pediatric patients with POMS treated with DMF were free of new or newly enlarging T2 lesions and that the adjusted ARR was lower among these patients compared with those tre... ClinicalTrials.gov Identifier: NCT02283853....

Impact of interferon beta exposure on birth outcome and child development - Results from the post-authorisation safety study PRIMA.

Interferon beta therapies are well-established disease-modifying treatments for patients with relapsing multiple sclerosis (MS). Based on clinical evidence from two large cohort studies, both, the EMA... The post-authorisation safety study PRIMA included adult women diagnosed with relapsing-remitting MS or clinically isolated syndrome, who were treated with peginterferon beta-1a or IM interferon beta-... In total, 426 women were enrolled, reporting 542 pregnancies that resulted in 466 live births. A total of 162 women completed the questionnaire for 192 live births (53.1% male). Newborns had Apgar sco... Study results confirmed former reports indicating that exposure to interferon beta therapies during pregnancy or lactation had no adverse effects on intrauterine growth and child development over the ... NCT04655222, EUPAS38347....